Cost-Effectiveness of Ketamine Versus ECT in US Depression Care

Ketamine and ECT: New Evidence on Cost-Effectiveness in Depression

A peer-reviewed study published on October 22, 2026, in PubMed (PMID: 42908073) offers the first direct cost-effectiveness comparison between ketamine and electroconvulsive therapy (ECT) for adults with nonpsychotic, treatment-resistant depression (TRD) in the United States. The analysis models clinical outcomes, health care costs, and quality-adjusted life years (QALYs) for both interventions, using data from randomized controlled trials and real-world health system sources.

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has gained attention as a rapid-acting antidepressant, while ECT remains a gold-standard intervention for severe TRD. Both treatments are typically considered after failure of at least two prior antidepressant regimens. The study's findings are significant because cost-effectiveness is a key determinant for insurance coverage and guideline adoption in US mental health care.

Mechanisms, Outcomes, and Comparative Value

Ketamine and ECT differ substantially in mechanism, administration, and patient experience. ECT induces controlled seizures under anesthesia, requiring multiple hospital visits and post-procedure monitoring. Ketamine is usually administered intravenously or intranasally, with effects often observed within hours, but requiring repeated dosing for sustained benefit. The study models direct medical costs (including procedure, monitoring, and follow-up) and indirect costs (such as time off work and adverse event management).

The cost-effectiveness analysis uses incremental cost-effectiveness ratios (ICERs) to compare the two treatments. The results suggest that, for nonpsychotic TRD, ketamine may offer similar or slightly superior cost-effectiveness compared to ECT, primarily due to lower procedure costs and reduced need for anesthesia and inpatient care. However, the durability of ketamine's antidepressant effect remains a critical variable: ECT's longer-term remission rates may offset its higher upfront costs in some scenarios.

• Primary source: PubMed study (PMID: 42908073)

Policy, Payer, and Research Implications

The study's cost-effectiveness data could influence insurance coverage decisions, clinical guidelines, and future research priorities for TRD. Payers may reconsider prior authorization requirements or expand coverage for ketamine, especially if further evidence supports its parity or superiority to ECT in both cost and outcomes. Clinical guidelines, such as those issued by the American Psychiatric Association (APA), may incorporate these findings into updated recommendations for sequencing or combining TRD interventions.

For policymakers, the study highlights the need for ongoing real-world data collection and head-to-head trials, particularly in diverse patient populations and health system settings. Notably, the analysis underscores that cost-effectiveness is context-dependent: regional pricing, health system infrastructure, and patient preferences can all shift the balance between ketamine and ECT. A non-obvious implication is that broader ketamine access could relieve pressure on ECT service capacity, potentially improving wait times and outcomes for patients who require ECT's unique benefits.

Risks, Unknowns, and Systemic Considerations

Despite promising findings, significant uncertainties remain. The long-term safety and efficacy of repeated ketamine administration are not yet fully established, with concerns about cognitive effects, dissociation, and potential for misuse. ECT, while effective, carries risks of cognitive side effects and stigma, which can limit patient acceptance and adherence.

The study's model relies on assumptions about relapse rates, maintenance therapy needs, and adverse event frequencies that may not fully capture real-world complexity. Additionally, insurance coverage for ketamine remains inconsistent across US payers, and regulatory frameworks for off-label use vary by state and institution. A real failure mode not widely discussed in competitor analyses is the risk of fragmented care: if ketamine is adopted without robust monitoring and follow-up infrastructure, patients may experience suboptimal outcomes or safety events that undermine its cost-effectiveness in practice.

Looking Forward: Evidence Gaps and Future Directions

As health systems and policymakers digest these findings, several priorities emerge. Longitudinal studies are needed to clarify the durability of ketamine's antidepressant effects and to identify patient subgroups most likely to benefit from each intervention. Comparative effectiveness research should also address patient-reported outcomes, functional recovery, and quality of life, not just symptom reduction and cost.

Stakeholders should monitor evolving payer policies, guideline updates, and new clinical trial data (including ongoing Phase III ketamine studies registered at ClinicalTrials.gov). The field will benefit from transparent, first-party data sharing and multi-stakeholder dialogue to ensure that cost-effectiveness translates into equitable, evidence-based access for patients with treatment-resistant depression.

Byline: Dr. Alex M. Carter, MD, MPH. Reviewed by Dr. Jamie Lin, PharmD, on 2026-10-23. Research based on primary literature and regulatory sources; see PubMed PMID: 42908073 for full details.